Quick Summary
- Anthony Mancini, Chief Global Commercialization Officer, offloaded 26,552 shares valued at approximately $3.5M on March 25 through a predetermined 10b5-1 trading arrangement
- Shares started trading at $94.29, reflecting a 1.3% decline, within its 52-week trading band of $29.17–$124.49
- On March 26, Truist Financial elevated its rating to “strong-buy,” aligning with positive calls from Jefferies, Evercore, UBS, and Wedbush
- Company insiders have divested approximately 149,592 shares (valued near $15M) over the last three months, though institutional stakes command 94.34% ownership
- Fourth quarter 2025 results showed a loss of $1.86 per share, falling short of the anticipated -$1.56 consensus due to elevated R&D and operational spending
Shares of Revolution Medicines (RVMD) began Wednesday trading on March 26 at $94.29, slipping 1.3% from the previous session.
Revolution Medicines, Inc., RVMD
The company’s Chief Global Commercialization Officer, Anthony Mancini, executed a sale of 26,552 shares on March 25, generating roughly $3.5 million in proceeds. The share disposal occurred across a price spectrum spanning $93.22 to $97.21.
These sales took place through a Rule 10b5-1 trading arrangement that Mancini established on December 24, 2025. Such predetermined plans allow executives to schedule transactions in advance, reducing concerns that the timing reflects negative insider sentiment about the company’s prospects.
Concurrently, Mancini exercised stock options to purchase 37,450 shares priced at $33.62 each, amounting to approximately $1.26 million. Following these combined activities, his direct holdings include 54,400 common shares plus an additional 54,400 restricted stock units.
Mancini’s transaction wasn’t isolated among company leadership. Mark A. Goldsmith, another insider, divested 12,871 shares on March 17 at an average price of $99.48, generating proceeds exceeding $1.28 million. Chief Financial Officer Jack Anders similarly sold 2,753 shares on the identical date at matching prices, yielding approximately $274,000.
Cumulatively, company insiders have sold roughly 149,592 shares valued at $15 million during the preceding 90-day period. Current insider ownership represents 8.20% of outstanding shares.
Wall Street Firms Issue Strong-Buy Signals
Notwithstanding the insider dispositions, Wall Street analysts maintain predominantly optimistic perspectives. Truist Financial elevated RVMD to “strong-buy” status on March 26.
Evercore issued an identical recommendation earlier on February 25. Jefferies launched coverage with a “buy” rating on March 16. UBS similarly initiated coverage with a “buy” designation on February 27.
The solitary bearish voice comes from Weiss Ratings, maintaining a “sell (d-)” stance. MarketBeat’s aggregated consensus reflects a “Buy” rating with an average price objective of $78.94—substantially beneath current market valuation.
Individual analyst targets paint a more aggressive picture. Piper Sandler elevated its target to $120 (Overweight rating), Wells Fargo established a $144 objective, and Needham projects $145 while maintaining a Buy recommendation.
Institutional Capital Floods In Despite Quarterly Shortfall
Institutional investment activity reveals substantial confidence. Norges Bank established a fresh position valued at approximately $195.6 million during Q4. Avoro Capital entered with roughly $172.8 million. UBS expanded its holdings by 183.6% to 3,087,937 shares, representing nearly $246 million in value. Polar Capital increased its stake by 321.2%, currently maintaining over 2 million shares.
Institutional investors collectively control 94.34% of RVMD.
This optimistic institutional positioning persists despite Revolution Medicines missing fourth quarter 2025 expectations. The biotech firm posted a loss of $1.86 per share, compared to analyst projections of -$1.56, representing a $0.30 shortfall. Management attributed the variance to research and development expenditures plus selling, general, and administrative costs exceeding forecasts.
Revenue generation wasn’t problematic—the company closed the quarter maintaining $2.03 billion in cash reserves and investments, partially facilitated by a strategic arrangement with Royalty Pharma. Wall Street analysts forecast full-year fiscal 2026 EPS of -$3.49.
RVMD maintains a 50-day moving average of $101.53 and a 200-day moving average of $78.24. The company’s market capitalization stands at $18.69 billion.
Across the trailing twelve months, RVMD has rallied 145%. The six-month performance shows gains of 112%.
